A comparison of peak sputum tobramycin concentration in patients with cystic fibrosis using jet and ultrasonic nebulizer systems

Chest

Volumn 111, Issue 4, 1997, Pages 955-962

  Eisenberg, Jay ^a   Pepe, Margaret ^b   Williams Warren, Judy ^c   Vasiliev, Michael ^d   Bruce Montgomery, A ^d   Smith, Arnold L ^e   Ramsey, Bonnie W ^c,f  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

^e University of Missouri   (United States)

^f UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

antibiotics; cystic fibrosis; nebulizer; Pseudomonas aeruginosa; tobramycin

Indexed keywords

TOBRAMYCIN;

ARTICLE; BACTERIAL PNEUMONIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CYSTIC FIBROSIS; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG SPUTUM LEVEL; DRUG UPTAKE; HEMOPTYSIS; HUMAN; INHALATIONAL DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NEBULIZATION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RANDOMIZED CONTROLLED TRIAL; THORAX PAIN;

EID: 0030999183     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.111.4.955     Document Type: Article

References (29)

1. Burns JL, Ramey BW, Smith AL. Clinical manifestations and treatment of pulmonary infections in cystic fibrosis. Adv Pediatr Infect Dis 1993; 8:53-66
2. Koch G, Hoiby N. Pathogenesis of cystic fibrosis. Lancet 1993; 341:1065-69
3. Turpin SV, Knowles MR. Treatment of pulmonary disease in patients with cystic fibrosis. In: Davis PB, ed. Cystic fibrosis. New York: Marcel Dekker, 1993; 277-344
4. Mendelman PM, Smith AL, Levy J, et al. Aminoglycosicle penetration, inactivation, and effeacy in cystic fibrosis. Am Rev Respir Dis 1985; 132:761-65
5. Levy J. Smith AL, Henny MA, et al. Bioactivity of gentamicin in purulent sputum from patients with cystic fibrosis or bronchiectasis: comparison with activity in sputum. J Infect Dis 1983; 148:1069-75
6. Pennington JE, Penetration of antibioties into respiratory secretions. Res Infect Dis 1981; 3:67-73
7. Moore RD, Smith CR, Lipsky JJ, et al. Risk factors for nephirotoxicity in patients treated with aminoglycosides. Ann Intern Med 1984; 100:352-57
8. Moore RD, Smith CR, Lietman PS. Risk factors for the development of auditory toxicity in patients receiving aminoglycosides. J Infect Dis 1984; 149:23-30
9. Gatell JM, Ferran F, Aranjo V, et al. Univariate and multivariate analyses of risk factors predisposing to auditory toxicity in patients receiving aminoglycosides, Antimicrob Agents Chemother 1987; 31:1383-87
10. Matz GJ. Aminoglycoside ototoxicity. Am J Otolayngol 1986; 7:117-19
11. Brummett RE. Drug-induced ototoxicity. Drugs 1980; 13: 412-28
12. Le Conte P, Potel G, Peltier P, et al. Lung distribution and phamacokinetics of aerosolized tobramyein. Am Rev Respir Dis 1993; 147:1279-82
13. MacLusky I, Levison H, Gold R, et al. Inhaled antibioties in cystic tibrosis: is there a therapeutic effect? J Pediatr 1986; 108:861-65
14. Hodson ME, Penketh ARL, Batten JC. Aerosol carbenicillin and gentamicin treatment of Pscudomonas aeruginosa infection in patients with cystic fibrosis. Lancet 1981; 2:1137-39
15. Wall MA. Terry AB, Eisenberg JD, et al. Inhaled antibiotics in cystic fibrosis [letter]. Lancet 1983; 1:1325
16. Stead RJ, Hodson ME, Batten JC. Inhaled ceftazidime compared with gentamicin and carbemicillin in older patients with cystic fibrosis infected with Pseudomonas aeruginosa. Br J Dis Chest 1987; 81:272-79
17. Steinkamp G, Tummler B, Gappa M, et al. Long-term tobramycin aerosol therapy in cystic fibrosis. Pediatr Pulmonol 1989; 6:91-8
18. Carswell F, Ward C, Cook DA, et al. A controlled trial of nebulized aminoglycoside and oral fluclovacillin versus placebo in the outpatient management of children with cystic fibrosis. Br J Dis Chest 1987: 81:856-60
19. MacLusky IB, Gold R, Corey M, et al. Long-term effects of inhaled tobramycin in patients with cystic fibrosis colonized with Pscudomonas aeruginos. Pediatr Pulmonol 1989; 7:42-8
20. Knn P, Landau LI, Phelan PD. Nebulized gentamicin in children and adoleseents with cystic fibrosis. Aust Paediatr J 1984; 20:43-5
21. Smith AL, Ramsey BW, Hedges DL, et al. Safety of aerosol tobramycin administration for 3 months to patients with cystic fibrosis. Pediatr Pulmonol 1989; 7:265-71
22. Ramsey BW, Dorkin HL, Eisenberg JD, et al. Effieacy of aerosolized tobramycin in in patients with cystic fibrosis. N Engl J Med 19993; 328:1740-46
23. Gibson LE, Cooke RE. A test tor concentration of electrolytes in sweat in cystic fibrosis of the pancreas utilizing pilocarpine by iontophoresis. Pediatrics 1959; 23:545-49
24. Kerem B, Rommens JM, Buchanan JA, et al. Identification of the cystic fibrosis gene: genetic analysis. Science 1989; 245: 1073-80
25. Kmidsen RJ, Lebowitz MD, Hollberg CJ, et al. Changes in the normal maximal expiratory flow-volume curve with growth and aging. Am Rev Respir Dis 1983; 127:725-34
26. Standardization of spirometry - 1987 update. Am Res Respir Dis 1987; 136:2285-98
27. Barends DM, Zwann CL, Hulshoff A. Micro-determination of tobramycin in serum bv high-perfomanace liquid chromatography with ultraviolet detection. J Chromatogr 1981; 225: 417-26
28. Jolley ME, Stroupe SD, Wang CJ, et al. Fluorescence polarization immunoassay: I. Monitoring aminoglycoside antibiotics in serum and plasma, Clin Chem 1981; 27: 1190-97
29. Nikolaizik WH, Jenni-Galovic V. Schoni MH, Bronchial constriction after nebulized tobramycin and saline in patients with cystic fibrosis [abstract]. Am J Respir Crit Care Med 1996; 153:A707